ARDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ardelyx Inc (ARDX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, positive analyst sentiment, and robust product pipeline outweigh the short-term technical weakness and insider selling. The current price dip presents a potential entry point for long-term gains.
The technical indicators show a bearish short-term trend with the MACD histogram below 0 and negatively expanding, RSI at 41.195 in the neutral zone, and converging moving averages. The stock is trading near its pivot level of 6.223, with support at 5.753 and resistance at 6.693. Despite the short-term weakness, the long-term outlook remains positive.
Analysts have consistently raised price targets, with the latest targets ranging from $13 to $19, citing strong revenue growth, a robust product pipeline, and extended intellectual property protection until
The company reported four consecutive years of revenue growth, with Q4 2025 revenue reaching $407.32 million.
Positive sentiment around the company's therapies, IBSRELA and XPHOZAH, which are driving revenue growth.
A new multi-year partnership with the LPGA to raise awareness of women's digestive health, potentially boosting brand visibility.
Hedge funds are selling, with a 129.11% increase in selling activity over the last quarter.
Insider selling by the CEO, who sold 41,666 shares recently.
Short-term technical indicators suggest bearish momentum.
Net income and EPS have declined significantly YoY, indicating profitability challenges.
In Q4 2025, revenue increased by 7.82% YoY to $125.215 million, gross margin improved to 91.34% (up 8.39% YoY), but net income dropped to -$407,000 (-108.76% YoY) and EPS fell to 0 (-100% YoY). The company is showing strong revenue growth but faces profitability challenges.
Analysts are highly bullish on ARDX, with multiple firms raising price targets significantly, citing strong revenue growth, a robust pipeline, and extended intellectual property protection. The consensus is a strong buy, with price targets ranging from $13 to $19.
